Top

Published in:

01-11-2020 | PCSK9 Inhibitor

Cost-effectiveness analysis of PCSK9 inhibitors in cardiovascular diseases: a systematic review

Authors: Samad Azari, Aziz Rezapour, Negar Omidi, Vahid Alipour, Masoud Behzadifar, Hossein Safari, Masih Tajdini, Nicola Luigi Bragazzi

Published in: Heart Failure Reviews | Issue 6/2020

Abstract

Aims

To assess the cost-effectiveness of pro-protein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in cardiovascular disease.

Methods and results

We performed a comprehensive search strategy in electronic databases from January 2015 to January 2019. Out of 475 articles, 16 were entered into the study. Quality-adjusted life year, life years gained (LYG), annual cost, and the incremental cost-effectiveness ratio (ICER) regarding the use of PCSK9 inhibitors were considered as the key outcomes. The cost-effectiveness threshold varied from $45,000 in Spain to $150,000 in the USA. The annual cost of PCSK9 inhibitors for studies undertaken in the USA was in the range of $14,000 to $15,000, while it was about $7000 for other developed countries. The results showed that reduction in the price of PCSK9 inhibitors changed from 20 to 88%. The means of QALY were 0.65 and 0.67 in the Markov and Cardiovascular Disease Policy Modeling (CVDPM) models; also, the ICER means were $197,707 and $625,555 for the Markov and CVDPM model, respectively.

Conclusion

According to the current study, the effectiveness of PCSK9 inhibitors is well documented, although all studies pointed out a higher cost of these inhibitors.

Trial registration

This study was registered within the International Prospective Register of Systematic Reviews (PROSPERO) database of the University of York (CRD42018088472).

Shah P (2018) Economic evaluation of the PCSK9 inhibitors in prevention of the cardiovascular diseases. Curr Cardiol Rep 20(7):51. https://doi.org/10.1007/s11886-018-0993-8CrossRefPubMed

Bloom DE, Cafiero E, Jané-Llopis E, Abrahams-Gessel S, Bloom LR, Fathima S, Feigl AB, Gaziano T, Hamandi A, Mowafi M (2012) The global economic burden of noncommunicable diseases. Program on the Global Demography of Aging

Naghavi M, Abajobir AA, Abbafati C, Abbas KM, Abd-Allah F, Abera SF, Aboyans V, Adetokunboh O, Afshin A, Agrawal A (2017) Global, regional, and national age-sex specific mortality for 264 causes of death, 1980–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet 390(10100):1151–1210CrossRef

GBD 2017 DALYs and HALE Collaborators (2018) Global, regional, and national disability-adjusted life-years (DALYs) for 359 diseases and injuries andhealthy life expectancy (HALE) for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet 392(10159):1859–1922. (London, England). https://doi.org/10.1016/s0140-6736(18)32335-3

Gandra SR, Villa G, Fonarow GC, Lothgren M, Lindgren P, Somaratne R, van Hout B (2016) Cost-effectiveness of LDL-C lowering with evolocumab in patients with high cardiovascular risk in the United States. Clin Cardiol 39(6):313–320CrossRef

Pecin I, Reiner Z (2015) Alirocumab: targeting PCSK9 to treat hypercholesterolemia. Drugs Today (Barc) 51(12):681–687. https://doi.org/10.1358/dot.2015.51.12.2435830CrossRef

Sabatine MS, De Ferrari GM, Giugliano RP, Huber K, Lewis BS, Ferreira J, Kuder JF, Murphy SA, Wiviott SD, Kurtz CE (2018) Clinical benefit of evolocumab by severity and extent of coronary artery disease: an analysis from FOURIER. Circulation 118:034309

Seidah NG, Benjannet S, Wickham L, Marcinkiewicz J, Jasmin SB, Stifani S, Basak A, Prat A, Chrétien M (2003) The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation. Proc Natl Acad Sci 100(3):928–933CrossRef

Robinson JG (2016) Nonstatins and proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: role in non-familial hypercholesterolemia. Prog Cardiovasc Dis 59(2):165–171. https://doi.org/10.1016/j.pcad.2016.07.011CrossRefPubMed

10.

Turgeon RD, Pearson GJ (2018) Proprotein convertase subtilisin/kexin type 9 inhibitors for reduction of cardiovascular events. Am J Health Syst Pharm 75(11):747–754CrossRef

11.

Stam-Slob MC, van der Graaf Y, de Boer A, Greving JP, Visseren FLJ (2018) Cost-effectiveness of PCSK9 inhibition in addition to standard lipid-lowering therapy in patients at high risk for vascular disease. Int J Cardiol 253:148–154. https://doi.org/10.1016/j.ijcard.2017.10.080CrossRefPubMed

12.

Toth PP, Worthy G, Gandra SR, Sattar N, Bray S, Cheng LI, Bridges I, Worth GM, Dent R, Forbes CA, Deshpande S, Ross J, Kleijnen J, Stroes ESG (2017) Systematic review and network meta-analysis on the efficacy of evolocumab and other therapies for the management of lipid levels in hyperlipidemia. J Am Heart Assoc 6(10). https://doi.org/10.1161/JAHA.116.005367

13.

Nasir K, Arrieta A, Veledar E (2015) Economic evaluations of PCSK9 inhibitors in reducing cardiovascular risk from societal & United States payer perspective. Circulation. 132

14.

Sabatine MS, Giugliano RP, Wiviott SD, Raal FJ, Blom DJ, Robinson J, Ballantyne CM, Somaratne R, Legg J, Wasserman SM (2015) Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N Engl J Med 372(16):1500–1509CrossRef

15.

Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, Kuder JF, Wang H, Liu T, Wasserman SM (2017) Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med 376(18):1713–1722CrossRef

16.

Drexel H (2018) Cost-effectiveness with PCSK9 inhibitors: a matter of costs. Eur Heart J Cardiovasc Pharmacother 4(1):23–24PubMed

17.

Kazi DS, Penko J, Coxson PG, Moran AE, Ollendorf DA, Tice JA, Bibbins-Domingo K (2017) Updated cost-effectiveness analysis of PCSK9 inhibitors based on the results of the FOURIER trial. JAMA 318(8):748–750. https://doi.org/10.1001/jama.2017.9924CrossRefPubMedPubMedCentral

18.

Kodera S, Morita H, Kiyosue A, Ando J, Takura T, Komuro I (2018) Cost-effectiveness of PCSK9 inhibitor plus statin in patients with triple-vessel coronary artery disease in Japan. Circ J https://doi.org/10.1253/circj.CJ-17-1455

19.

Arrieta A, Hong JC, Khera R, Virani SS, Krumholz HM, Nasir K (2017) Updated cost-effectiveness assessments of PCSK9 inhibitors from the perspectives of the health system and private payers insights derived from the FOURIER trial. JAMA Cardiol 2(12):1369–1374. https://doi.org/10.1001/jamacardio.2017.3655CrossRefPubMedPubMedCentral

20.

Arrieta A, Page TF, Veledar E, Nasir K (2017) Economic evaluation of PCSK9 inhibitors in reducing cardiovascular risk from health system and private payer perspectives. PLoS One 12(1):e0169761. https://doi.org/10.1371/journal.pone.0169761CrossRefPubMedPubMedCentral

21.

Husereau D, Drummond M, Petrou S, Carswell C, Moher D, Greenberg D, Augustovski F, Briggs AH, Mauskopf J, Loder E (2013) Consolidated health economic evaluation reporting standards (CHEERS) statement. Cost Eff Resour Alloc 11(1):6CrossRef

22.

Villa G, Lothgren M, Kutikova L, Lindgren P, Gandra SR, Fonarow GC, Sorio F, Masana L, Bayes-Genis A, van Hout B (2017) Cost-effectiveness of evolocumab in patients with high cardiovascular risk in Spain. Clin Ther 39(4):771–786 e773CrossRef

23.

Korman M, Wisloff T (2018) Modelling the cost-effectiveness of PCSK9 inhibitors vs. ezetimibe through LDL-C reductions in a Norwegian setting. European heart journal Cardiovascular pharmacotherapy 4(1):15–22. https://doi.org/10.1093/ehjcvp/pvx010CrossRefPubMed

24.

Tice J, Ollendorf D, Cunningham C, Pearson S, Kazi D, Coxson P (2015) PCSK9 inhibitors for treatment of high cholesterol: effectiveness, value, and value-based price benchmarks: final report. The Institute for Clinical and Economic Review (ICER)

25.

26.

ICER (2017) Evolocumab for treatment of high cholesterol: clinical effectiveness. Institute for Clinical and Economic Review, Usa

27.

ICER (2018) Alirocumab for treatment of high cholesterol: effectiveness and value preliminary new evidence update. Institute for Clinical and Economic Review, Usa

28.

Kumar R, Tonkin A, Liew D, Zomer E (2018) The cost-effectiveness of PCSK9 inhibitors - the Australian healthcare perspective. Int J Cardiol 267:183–187. https://doi.org/10.1016/j.ijcard.2018.04.122CrossRefPubMed

29.

Kazi DS, Moran AE, Coxson PG, Penko J, Ollendorf DA, Pearson SD, Tice JA, Guzman D, Bibbins-Domingo K (2016) Cost-effectiveness of PCSK9 inhibitor therapy in patients with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease. Jama 316(7):743–753. https://doi.org/10.1001/jama.2016.11004CrossRefPubMed

30.

Fonarow GC, Keech AC, Pedersen TR, Giugliano RP, Sever PS, Lindgren P, van Hout B, Villa G, Qian Y, Somaratne R (2017) Cost-effectiveness of evolocumab therapy for reducing cardiovascular events in patients with atherosclerotic cardiovascular disease. JAMA Cardiol 2(10):1069–1078CrossRef

31.

Ting EE, Sander B, Ungar WJ (2017) Systematic review of the cost-effectiveness of influenza immunization programs. Vaccine 35(15):1828–1843CrossRef

Title: Cost-effectiveness analysis of PCSK9 inhibitors in cardiovascular diseases: a systematic review
Authors: Samad Azari
Aziz Rezapour
Negar Omidi
Vahid Alipour
Masoud Behzadifar
Hossein Safari
Masih Tajdini
Nicola Luigi Bragazzi
Publication date: 01-11-2020
Publisher: Springer US
Keywords: PCSK9 Inhibitor
Evolocumab
Alirocumab
Published in: Heart Failure Reviews / Issue 6/2020
Print ISSN: 1382-4147
Electronic ISSN: 1573-7322
DOI: https://doi.org/10.1007/s10741-019-09874-2

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

At a glance: The STEP trials

Springer Medicine

Cost-effectiveness analysis of PCSK9 inhibitors in cardiovascular diseases: a systematic review

Abstract

Aims

Methods and results

Conclusion

Trial registration

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The STEP trials

Springer Medicine

Abstract

Aims

Methods and results

Conclusion

Trial registration

Please log in to get access to this content

Other articles of this Issue 6/2020

Cavitation in left ventricular assist device patients: a potential early sign of pump thrombosis

Basic and advanced echocardiography in advanced heart failure: an overview

A manifesto of collaborative longitudinal cardiovascular care in heart failure

Non-vitamin K antagonist oral anticoagulants in Asian patients with atrial fibrillation: evidences from the real-world data

“The heart supporters”: systematic review for ventricle assist devices in congenital heart surgery

Quality of life of chronic heart failure patients: a systematic review and meta-analysis

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page